Lisocabtagene maraleucel as second-line therapy for adult patients with LBCL: Primary analysis of the phase III TRANSFORM trial

Primary analysis of the phase III TRANSFORM trial indicates that...

DESCAR-T analysis: outcomes following anti-CD19 CAR T-cell failure

In this article, we summarize an analysis by Di Blasi et al. on outcomes after CAR T-cell failure and a follow-up analysis of the CAR...

A phase I/II trial of pirtobrutinib in patients with R/R Waldenstrom’s macroglobulinemia (BRUIN trial)

Data from the ongoing phase I/II BRUIN clinical trial were presented at #ASH22. Pirtobrutinib...

Novel combinations for R/R MCL: Key updates from ASH 2022

The article predominantly focuses on results presented at ASH 2022 from interventional studies of novel combination therapies in...

Educational theme | Latest advances in the treatment for patients with Hodgkin lymphoma

We highlight the latest advances in the treatment of HL presented at the European Hematology Association (EHA)...

Emerging novel therapies for the treatment of patients with aggressive R/R NHL

Despite the success of chimeric antigen receptor (CAR) T-cell therapies in patients with relapsed/refractory (R/R)...

Phase I data of golidocitinib for R/R peripheral T-cell lymphoma: JACKPOT8 trial

The study met its primary endpoint, elucidating the adverse events associated with golidocitinib in patients with R/R...

Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment?

During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek Trněný, Charles University, Prague,...

Responses to the SARS-CoV-2 booster vaccination in patients with lymphoid malignancies

Here, we provide a summary of two papers investigating humoral and T-cell-mediated responses in patients with...

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We...

COVID-19 severity, mortality, and mRNA vaccine responses in patients with CLL

Since the first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, more than 3 million people...

Humoral and cellular responses in patients with lymphoid malignancies receiving SARS-Cov-2 vaccination

Factors that influence the efficacy of Severe Acute Respiratory Syndrome Coronavirus-2...

What are the latest treatment advances for Hodgkin lymphoma?

During the 2022 ASCO Annual Meeting, the Lymphoma Hub spoke with Alison Moskowitz, Feinstein Institutes for Medical Research, New York, US....

What is on the horizon for the frontline treatment of MCL?

During the ASCO 2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York,...

Latest advances in the treatment of mantle cell lymphoma

The current and future treatment landscape for MCL looks hopeful, with the development of new treatment regimens and novel therapeutics that...

CAPTIVATE 3-year update: fixed-duration ibrutinib + venetoclax in CLL/SLL

The 3-year follow-up of the FD cohort showed that I + V continues to demonstrate deep and durable responses, with a clinically...